Novavax to Participate in Multiple Investor Conferences in September

GAITHERSBURG, Md., Sept. 02, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the Company will participate in the FBR 2nd Annual Healthcare Conference and the Citi 10th Annual Biotech Conference.

Conference details are as follows:

FBR 2nd Annual Healthcare Conference

Date: Wednesday, September 9, 2015
Forum: One-on-one meetings 
Location: Four Seasons Hotel, Boston

Citi 10th Annual Biotech Conference

Date: Thursday, September 10, 2015
Forum: Panel discussion, Preventing and Treating Viral Infections: Vaccines and Antivirals
Time: 8:00 - 8:55 a.m. US Eastern Time
Location: Mandarin Oriental Hotel, New York

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website, novavax.com.

Contact: Novavax, Inc.

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations

ir@novavax.com  
240-268-2000

Russo Partners, LLC

David Schull
Todd Davenport, Ph.D.

david.schull@russopartnersllc.com 
todd.davenport@russopartnersllc.com
212-845-4271